Target Organs and Levels of Evidence for TR-589
TR-589 Toxicology Studies of a Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] (CAS No. 32534-81-9) in F344/N Rats and B6C3F1/N Mice and Toxicology and Carcinogenesis Studies of a Pentabromodiphenyl Ether Mixture [DE-71 (Technical Grade)] in Wistar Han [Crl:WI(Han)] Rats and B6C3F1/N Mice (Gavage Studies)
Chemical
CASRN
(Study Title) |
Peer Review Date |
Primary Uses |
Route/Exposure Levels |
Study Laboratory |
Pentabromodiphenyl Ether (Technical) (DE 71)
32534-81-9 |
06/25/2015 |
Flame retardant |
Gavage
M: 0, 3, 30, or 100 mg/kg; 50/sex/dose |
Southern Research Institute |
Levels of Evidence
Male Mice: Clear Evidence
| Type |
Organ/Tissue (Lesion) |
| Neoplastic Lesions |
- Liver: hepatocellular adenoma 23/50 35/50 49/50 40/50 hepatocellular carcinoma 18/50 15/50 30/50 45/50 hepatocellular adenoma or carcinoma 31/50 40/50 49/50 47/50 hepatoblastoma 1/50 1/50 16/50 5/50 hepatocellular adenoma, hepatocellular carcinoma, or hepatoblastoma 31/50 40/50 49/50 47/50
|
| Non-Neoplastic Lesions |
- Liver: centrilobular, hepatocyte, hypertrophy; clear cell focus; necrosis, focal; Kupffer cell, pigmentation
- Thyroid gland: follicle, hypertrophy
- Forestomach: epithelium, hyperplasia; inflammation
- Adrenal cortex: hypertrophy, diffuse
- Testes: germinal epithelium, atrophy
|
Female Mice: Clear Evidence
| Type |
Organ/Tissue (Lesion) |
| Neoplastic Lesions |
- Liver: hepatocellular adenoma 5/50 7/49 32/50 46/49 hepatocellular carcinoma 4/50 2/49 6/50 27/49 hepatocellular adenoma or carcinoma 8/50 8/49 33/50 47/49
|
| Non-Neoplastic Lesions |
- Liver: centrilobular, hepatocyte, hypertrophy; eosinophilic focus; fatty change; Kupffer cell, pigmentation
- Thyroid gland: follicle, hypertrophy
- Forestomach: epithelium, hyperplasia
- Adrenal cortex: hypertrophy, diffuse
|
Chemical
CASRN
(Study Title) |
Peer Review Date |
Primary Uses |
Route/Exposure Levels |
Study Laboratory |
Pentabromodiphenyl Oxide (Technical) (DE 71)
32534-81-9 |
06/02/2015 |
Flame retardant |
Gavage
R: 0, 3, 15, or 50 mg/kg; 50/sex/dose |
Southern Research Institute |
Levels of Evidence
Male Rats: Clear Evidence
| Type |
Organ/Tissue (Lesion) |
| Neoplastic Lesions |
- Liver: hepatocellular adenoma or carcinoma 3/49 2/50 4/50 9/50; hepatocholangioma, hepatocellular adenoma, or hepatocellular carcinoma 3/49 2/50 4/50 11/50
- Thyroid Gland Follicular Cell: adenoma 1/45 3/45 2/48 6/46
- Pituitary Gland: (pars distalis): adenoma 19/49 12/49 22/50 35/50
|
| Non-Neoplastic Lesions |
- Liver: eosinophilic focus; hepatocyte, hypertrophy; fatty change
- Thyroid gland: follicle, hypertrophy
- Kidney: hydronephrosis
- Parotid salivary gland: atrophy; cytoplasmic vacuolization
- Prostate gland: inflammation, chronic active
- Preputial gland: duct, ectasia
- Thymus: atrophy
- Forestomach: epithelium hyperplasia
|
Female Rats: Clear Evidence
| Type |
Organ/Tissue (Lesion) |
| Neoplastic Lesions |
- Liver: cholangiocarcinoma 0/50 0/49 0/50 2/47 hepatocholangioma 0/50 0/49 0/50 8/47 hepatocellular adenoma 3/50 2/49 8/50 16/47 hepatocellular carcinoma 0/50 0/49 1/50 6/47 hepatocellular adenoma or carcinoma 3/50 2/49 8/50 17/47) hepatocholangioma, hepatocellular adenoma, or hepatocellular carcinoma 3/50 2/49 8/50 21/47
|
| May Have Been Related |
- Uterus: stromal polyp or stromal sarcoma (original and residual evaluations, combined) 4/50 12/50 12/50 9/49
|
| Non-Neoplastic Lesions |
- Liver: hyperplasia, nodular; eosinophilic focus; hepatocyte, hypertrophy; fatty change; oval cell, hyperplasia
- Thyroid gland: follicle, hypertrophy; follicular cell hyperplasia
- Uterus: squamous metaplasia
- Cervix: squamous hyperplasia
- Kidney: hydronephrosis
- Adrenal cortex: focal hyperplasia
|
